HLXB
NASDAQHelix Acquisition Corp. II
IPO2024
Price$9.80-1.04 (-9.59%)
2025-06-092025-08-11
News · 26 weeks10%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- PRBBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate ProgressBBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520's differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT's intern
- PRBBOT Reports Third Quarter 2025 Financial Results and Update on Corporate ProgressBBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar
- SECSEC Form S-1 filed by Helix Acquisition Corp. IIS-1 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
- INSIDERSEC Form 4 filed by Director Tipirneni Praveen P.4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Director Mccormick Frank4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Director Bauer Jake4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Beltran Pedro4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Chief Med & Dev Officer Ben Yong4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Wallace Eli M.4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Mehra Uneek4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- SECSEC Form EFFECT filed by Helix Acquisition Corp. IIEFFECT - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
- SECSEC Form SCHEDULE 13G filed by Helix Acquisition Corp. IISCHEDULE 13G - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)
- INSIDERSEC Form 3 filed by new insider Tipirneni Praveen P.3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Doig Michelle3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mccormick Frank3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERNew insider Bridgebio Pharma Llc claimed ownership of 13,805,126 shares (SEC Form 3)3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bauer Jake3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kumar Neil3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ben Yong3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wallace Eli M.3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mehra Uneek3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Beltran Pedro3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Helix Acquisition Corp. IISCHEDULE 13D/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)
- INSIDERDirector Chen Bihua converted options into 4,172,126 shares, returned 152,940 shares to the company and was granted 10,950,408 shares (SEC Form 4)4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
- SECHelix Acquisition Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Changes in Control of Registrant, Leadership Update, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
HLXB FAQ
3 questionsWhere does HLXB stock trade?
Helix Acquisition Corp. II (HLXB) is listed on NASDAQ.When did Helix Acquisition Corp. II go public?
Helix Acquisition Corp. II (HLXB) completed its IPO in 2024.How can I track HLXB on Quantisnow?
Quantisnow aggregates Helix Acquisition Corp. II's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HLXB to receive live email and push alerts on every new disclosure.